Logo image of ORGO

ORGANOGENESIS HOLDINGS INC (ORGO) Stock Fundamental Analysis

USA - NASDAQ:ORGO - US68621F1021 - Common Stock

4.86 USD
-0.1 (-2.02%)
Last: 9/16/2025, 8:00:02 PM
4.9186 USD
+0.06 (+1.21%)
After Hours: 9/16/2025, 8:00:02 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ORGO. ORGO was compared to 540 industry peers in the Biotechnology industry. ORGO has only an average score on both its financial health and profitability. ORGO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

ORGO had negative earnings in the past year.
In the past year ORGO has reported a negative cash flow from operations.
ORGO had positive earnings in 4 of the past 5 years.
Each year in the past 5 years ORGO had a positive operating cash flow.
ORGO Yearly Net Income VS EBIT VS OCF VS FCFORGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

ORGO's Return On Assets of -3.38% is amongst the best of the industry. ORGO outperforms 87.59% of its industry peers.
With an excellent Return On Equity value of -4.32%, ORGO belongs to the best of the industry, outperforming 89.81% of the companies in the same industry.
Industry RankSector Rank
ROA -3.38%
ROE -4.32%
ROIC N/A
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)N/A
ROIC(5y)N/A
ORGO Yearly ROA, ROE, ROICORGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

ORGO's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 74.58%, ORGO belongs to the top of the industry, outperforming 82.59% of the companies in the same industry.
ORGO's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for ORGO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.58%
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
ORGO Yearly Profit, Operating, Gross MarginsORGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

5

2. Health

2.1 Basic Checks

ORGO does not have a ROIC to compare to the WACC, probably because it is not profitable.
ORGO has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, ORGO has more shares outstanding
The debt/assets ratio for ORGO has been reduced compared to a year ago.
ORGO Yearly Shares OutstandingORGO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ORGO Yearly Total Debt VS Total AssetsORGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 4.90 indicates that ORGO is not in any danger for bankruptcy at the moment.
ORGO's Altman-Z score of 4.90 is fine compared to the rest of the industry. ORGO outperforms 75.37% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that ORGO is not too dependend on debt financing.
ORGO has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: ORGO outperforms 49.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.9
ROIC/WACCN/A
WACC9.89%
ORGO Yearly LT Debt VS Equity VS FCFORGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

ORGO has a Current Ratio of 3.95. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.95, ORGO is in line with its industry, outperforming 45.00% of the companies in the same industry.
ORGO has a Quick Ratio of 3.45. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
ORGO's Quick ratio of 3.45 is in line compared to the rest of the industry. ORGO outperforms 42.22% of its industry peers.
Industry RankSector Rank
Current Ratio 3.95
Quick Ratio 3.45
ORGO Yearly Current Assets VS Current LiabilitesORGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for ORGO have decreased strongly by -225.00% in the last year.
Measured over the past years, ORGO shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -37.90% on average per year.
ORGO shows a decrease in Revenue. In the last year, the revenue decreased by -4.20%.
The Revenue has been growing by 13.05% on average over the past years. This is quite good.
EPS 1Y (TTM)-225%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%-350%
Revenue 1Y (TTM)-4.2%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%-22.44%

3.2 Future

Based on estimates for the next years, ORGO will show a very strong growth in Earnings Per Share. The EPS will grow by 20.28% on average per year.
ORGO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.92% yearly.
EPS Next Y-112%
EPS Next 2Y-11.68%
EPS Next 3Y20.28%
EPS Next 5YN/A
Revenue Next Year4.04%
Revenue Next 2Y14.25%
Revenue Next 3Y12.92%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ORGO Yearly Revenue VS EstimatesORGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
ORGO Yearly EPS VS EstimatesORGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ORGO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
ORGO is valuated quite expensively with a Price/Forward Earnings ratio of 36.65.
Based on the Price/Forward Earnings ratio, ORGO is valued cheaply inside the industry as 90.00% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 22.71. ORGO is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 36.65
ORGO Price Earnings VS Forward Price EarningsORGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

89.07% of the companies in the same industry are more expensive than ORGO, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 176.08
ORGO Per share dataORGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

ORGO's earnings are expected to grow with 20.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.68%
EPS Next 3Y20.28%

More info and screens

0

5. Dividend

5.1 Amount

ORGO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORGANOGENESIS HOLDINGS INC

NASDAQ:ORGO (9/16/2025, 8:00:02 PM)

After market: 4.9186 +0.06 (+1.21%)

4.86

-0.1 (-2.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners54.13%
Inst Owner Change7.15%
Ins Owners31.29%
Ins Owner Change0.23%
Market Cap616.54M
Analysts85
Price Target8.16 (67.9%)
Short Float %15.11%
Short Ratio13.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-73%
Min EPS beat(2)-73%
Max EPS beat(2)-73%
EPS beat(4)2
Avg EPS beat(4)278.21%
Min EPS beat(4)-73%
Max EPS beat(4)688.24%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.3%
Min Revenue beat(2)-6.36%
Max Revenue beat(2)-4.23%
Revenue beat(4)2
Avg Revenue beat(4)1.61%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)13.3%
Revenue beat(8)4
Avg Revenue beat(8)0.38%
Revenue beat(12)5
Avg Revenue beat(12)0.07%
Revenue beat(16)6
Avg Revenue beat(16)-0.09%
PT rev (1m)14.29%
PT rev (3m)28%
EPS NQ rev (1m)-31.25%
EPS NQ rev (3m)-35.29%
EPS NY rev (1m)33.33%
EPS NY rev (3m)-153.33%
Revenue NQ rev (1m)-3.23%
Revenue NQ rev (3m)-3.64%
Revenue NY rev (1m)-0.96%
Revenue NY rev (3m)-0.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 36.65
P/S 1.44
P/FCF N/A
P/OCF N/A
P/B 1.71
P/tB 1.92
EV/EBITDA 176.08
EPS(TTM)-0.05
EYN/A
EPS(NY)0.13
Fwd EY2.73%
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS3.39
BVpS2.85
TBVpS2.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.38%
ROE -4.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.58%
FCFM N/A
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)4.79%
ROCE(5y)9.27%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
F-Score3
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0.03
Cap/Depr 74.48%
Cap/Sales 3.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.95
Quick Ratio 3.45
Altman-Z 4.9
F-Score3
WACC9.89%
ROIC/WACCN/A
Cap/Depr(3y)177.81%
Cap/Depr(5y)208.05%
Cap/Sales(3y)5.07%
Cap/Sales(5y)5.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-225%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%-350%
EPS Next Y-112%
EPS Next 2Y-11.68%
EPS Next 3Y20.28%
EPS Next 5YN/A
Revenue 1Y (TTM)-4.2%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%-22.44%
Revenue Next Year4.04%
Revenue Next 2Y14.25%
Revenue Next 3Y12.92%
Revenue Next 5YN/A
EBIT growth 1Y-221.35%
EBIT growth 3Y-33.42%
EBIT growth 5YN/A
EBIT Next Year510.28%
EBIT Next 3Y111.89%
EBIT Next 5YN/A
FCF growth 1Y-140.26%
FCF growth 3Y-48.6%
FCF growth 5YN/A
OCF growth 1Y-297.24%
OCF growth 3Y-38.8%
OCF growth 5YN/A